Cargando…
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Metastatic tumour recurrence due to failed treatments remains a major challenge of breast cancer clinical management. Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer (TNBC), where it ac...
Autores principales: | Wee, Zhen Ning, Yatim, Siti Maryam J. M., Kohlbauer, Vera K, Feng, Min, Goh, Jian Yuan, Yi, Bao, Lee, Puay Leng, Zhang, Songjing, Wang, Pan Pan, Lim, Elgene, Tam, Wai Leong, Cai, Yu, Ditzel, Henrik J, Hoon, Dave S. B., Tan, Ern Yu, Yu, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640083/ https://www.ncbi.nlm.nih.gov/pubmed/26503059 http://dx.doi.org/10.1038/ncomms9746 |
Ejemplares similares
-
Correction: Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
por: Wee, Zhen Ning, et al.
Publicado: (2015) -
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
por: Bao, Yi, et al.
Publicado: (2020) -
Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy
por: Ma, Shijun, et al.
Publicado: (2022) -
Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
por: Wang, Panpan, et al.
Publicado: (2020) -
Nonhematopoietic IRAK1 drives arthritis via neutrophil chemoattractants
por: Hoyler, Thomas, et al.
Publicado: (2022)